{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Pharmacokinetics (PK) of bempegaldesleukin and nivolumab derived from serum concentration versus time data.","groups":[{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 4.5 mg/kg administered intravenously every 3 weeks","id":"OG000","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)"},{"description":"Bempegaldesleukin 0.006 mg/kg + Nivolumab 360 mg administered intravenously every 3 weeks","id":"OG001","title":"Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)"}],"populationDescription":"Data was not and will never be collected","reportingStatus":"POSTED","timeFrame":"From first dose to 30 days after last dose (up to approximately 6 months)","title":"Area Under the Plasma Concentration (AUC) - Part A","type":"PRIMARY"}